Dr. Kong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11100 Euclid Avenue
Cleveland, OH 44106Phone+1 216-286-6740Fax+1 216-201-6623
Summary
- Yes I am an American board certified radiation oncologist and Professor with over 200 publications and NIH R01 grant. I had postdoctoral training from Duke University Medical Center, and finished my radiation oncology residency program at Washington University at St. Louis.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Radiation Oncology, 1999 - 2003
University of Vermont Medical CenterInternship, Transitional Year, 1998 - 1999
Shanghai Medical UniversityClass of 1985
Certifications & Licensure
OH State Medical License 2018 - 2026
GA State Medical License 2013 - 2019
IN State Medical License 2016 - 2019
MI State Medical License 2003 - 2016
VT State Medical License 1998 - 1999
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer Start of enrollment: 2007 May 01
- Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer Start of enrollment: 2008 Aug 01
- Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer Start of enrollment: 2012 Feb 22
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsGenetic Variations in the Transforming Growth Factor-β1 Pathway May Improve Predictive Power for Overall Survival in Non-small Cell Lung Cancer.Hong Zhang, Weili Wang, Pi Wenhu, Nan Bi, Colleen DesRosiers
Frontiers in Oncology. 2021-07-07 - 37 citationsLocal Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung CancerPercy Lee, Billy W. Loo, Tithi Biswas, George X. Ding, Issam El Naqa
International Journal of Radiation Oncology, Biology, Physics. 2021-05-01 - 50 citationsOrgans at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?Feng-Ming Spring Kong, Vitali Moiseenko, J. Zhao, Michael T. Milano, Ling Li
International Journal of Radiation Oncology, Biology, Physics. 2021-05-01
Journal Articles
- Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung CancerFeng-Ming Kong, Nirav Kapadia, The Annals of Thoracic Surgery
Lectures
- The effect of thoracic radiation on overall survival and their association with systemic immune therapy in stage IV NSCLC: Findings from the National Cancer Database.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Long-term survival comparison of stereotactic radiotherapy versus surgery for elderly patients with clinical stage T1-T2 non-small cell lung cancer.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
